Curated News
By: NewsRamp Editorial Staff
November 13, 2026
Quantum BioPharma Q3 2026: Stronger Balance Sheet, Lucid-MS Trial Advances
TLDR
- Quantum BioPharma cut Q3 opex 24% and grew equity 91%, strengthening its position to advance the Lucid-MS Phase 2 trial.
- Quantum BioPharma's Q3 results show cash and digital assets of $12.22 million, a narrowed net loss, and a Thermo Fisher agreement to start its Lucid-MS Phase 2 trial.
- Quantum BioPharma's progress on Lucid-MS for progressive multiple sclerosis could lead to new treatments that improve patients' quality of life.
- Quantum BioPharma's Lucid-MS is a patented new chemical entity that prevented and reversed myelin degradation in preclinical models of multiple sclerosis.
Impact - Why it Matters
Quantum BioPharma’s third-quarter results demonstrate a strengthening financial position that supports its planned operations for at least the next year, reducing near-term financing risk. The company’s progress in advancing Lucid-MS into a Phase 2 trial with Thermo Fisher Scientific marks a critical step toward addressing progressive multiple sclerosis, a condition with limited treatment options. For investors, the improved liquidity, reduced operating expenses, and narrowed net loss signal better operational efficiency and disciplined cost management. The agreement with Thermo Fisher, a global leader in clinical research, lends credibility to Quantum’s development program and could accelerate timelines. Additionally, the company’s retained stake and royalty interest in Unbuzzd provide a potential long-term revenue stream. Overall, this news matters because it reflects tangible progress in both financial health and clinical execution for a small biopharma with high-risk, high-reward potential.
Summary
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders, reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026. The company highlighted improved liquidity, with cash and cash equivalents of approximately $3.56 million and digital assets of $8.66 million, totaling $12.22 million compared to $4.12 million at year-end 2025. Shareholders’ equity increased 91% to $9.77 million, and working capital rose to $5.47 million from $420,000. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million. Operating cash use fell 21% for the first nine months of 2026, and notes payable decreased to $300,000 after repaying $1 million in debt.
Following the quarter, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. This follows FDA clearance of the company’s Investigational New Drug application in August 2026. Lucid-MS is a patented new chemical entity shown preclinically to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Management stated that its cash and digital asset holdings are sufficient to support planned operations over the next 12 months. To view the full press release, visit https://ibn.fm/GJ1ER.
Quantum is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on Lucid-MS. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% rights to develop similar products for pharmaceutical and medical uses. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Q3 2026: Stronger Balance Sheet, Lucid-MS Trial Advances
